NCT00296777 is a Phase 4 clinical trial of Escitalopram in Major Depression, sponsored by New York State Psychiatric Institute.

Who is sponsoring NCT00296777?

NCT00296777 is sponsored by New York State Psychiatric Institute.

What drugs are being tested in NCT00296777?

Interventions in NCT00296777: Escitalopram, Bupropion, Imipramine.

What condition does NCT00296777 study?

NCT00296777 studies Major Depression, Dysthymia.

Is NCT00296777 still recruiting?

NCT00296777 is currently completed. Last updated 26 April 2012.

Last reviewed 2012-04-26 · How we verify

NCT00296777

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment

Completed Phase 4 Last updated 26 April 2012

What this trial tests

Phase 4 trial testing Escitalopram in Major Depression in 28 participants. Completed in 1 December 2007.

Timeline

1 December 2004

Primary endpoint
1 May 2007

1 December 2007

Quick facts

Lead sponsor	New York State Psychiatric Institute
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	1 December 2004
Primary completion	1 May 2007
Estimated completion	1 December 2007
Sites	1 location across United States

Drugs / interventions tested

Escitalopram (escitalopram) — full drug profile →
Bupropion (bupropion) — full drug profile →
Imipramine (IMIPRAMINE) — full drug profile →

Conditions studied

Major Depression — all drugs for Major Depression →
Dysthymia — all drugs for Dysthymia →

Sponsor

New York State Psychiatric Institute

Who can join

Adults 18 to 65, any sex, with Major Depression or Dysthymia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hamilton Depression Scale (HAM-D)
Time frame: 7 mos.

Sponsor's own description

The main purpose of this study is to correlate brain testing with treatment outcome.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Understanding nerve-tumor interactions: From basic biology to therapeutic innovation.
Sun L, Li X, Wang Y, Wang J, et al · · 2026 · PMID 41938710 · DOI 10.1016/j.gendis.2025.101955

Verify or expand the search:

Other trials of Escitalopram

Trials testing the same drug.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07331987 — Efficacy and Safety of Probiotics for Anxiety Depression · NA · not yet recruiting
NCT06216535 — Escitalopram in Asthma Patients With Frequent Exacerbation · Phase 2 · recruiting
NCT06937476 — Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole · NA · active not recruiting
NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting

Other recruiting trials for Major Depression

Currently open trials in the same condition.

NCT07031817 — Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Di · NA · recruiting
NCT07184697 — Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD. · NA · active not recruiting
NCT07463911 — Treatment Response In ECT Patients · active not recruiting
NCT06763081 — Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation · recruiting
NCT06781593 — Combining Light Therapy and CPAP in Depression · NA · recruiting

Other New York State Psychiatric Institute trials

Trials by the same sponsor.

NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00296777 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
Last refreshed: 26 April 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00296777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing